CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer
<p>Abstract</p> <p>Background</p> <p>Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer (LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used serum marker in breast cancer.</p> <p>Methods<...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2006-09-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/6/220 |
| _version_ | 1811329405293690880 |
|---|---|
| author | McDermott Enda W Myers Eddie Kelly Gabrielle Al-azawi Dhafir Hill Arnold DK Duffy Michael J Higgins Niall O |
| author_facet | McDermott Enda W Myers Eddie Kelly Gabrielle Al-azawi Dhafir Hill Arnold DK Duffy Michael J Higgins Niall O |
| author_sort | McDermott Enda W |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer (LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used serum marker in breast cancer.</p> <p>Methods</p> <p>We retrospectively investigated the role of CA 15-3 in conjunction with other clinico-pathological variables as a predictor of response and time to disease recurrence following treatment in LABC. Pre and post primary chemotherapy serum concentrations of CA 15-3 together with other variables were reviewed and related to four outcomes following primary chemotherapy (clinical response, pathological response, time to recurrence and time to progression). Persistently elevated CA 15-3 after PC was considered as consecutively high levels above the cut off point during and after PC.</p> <p>Results</p> <p>73 patients were included in this study. Patients received PC (AC or AC-T regimen) for locally advanced breast cancer. 54 patients underwent surgery. The median follow up was 790 days. Patients with high concentrations of CA 15-3 before PC treatment had a poor clinical (<it>p </it>= 0.013) and pathological (<it>p </it>= 0.044) response. Together with Her-2/neu expression (<it>p </it>= 0.009) and tumour lympho-vascular space invasion (LVI) (<it>p </it>= 0.001), a persistently elevated CA 15-3 post PC (<it>p </it>= 0.007) was an independent predictive factor of recurrence following treatment in LABC.</p> <p>Conclusion</p> <p>Elevated CA 15-3 level is predictive of a poor response to chemotherapy. In addition, persistently elevated CA 15-3 levels post chemotherapy in conjunction with lympho-vascular invasion and HER2 status predict a reduced disease free survival following treatment in locally advanced breast cancer.</p> |
| first_indexed | 2024-04-13T15:43:20Z |
| format | Article |
| id | doaj.art-a88d726acb2e4177b1757292ef5d808e |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-13T15:43:20Z |
| publishDate | 2006-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-a88d726acb2e4177b1757292ef5d808e2022-12-22T02:41:04ZengBMCBMC Cancer1471-24072006-09-016122010.1186/1471-2407-6-220CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancerMcDermott Enda WMyers EddieKelly GabrielleAl-azawi DhafirHill Arnold DKDuffy Michael JHiggins Niall O<p>Abstract</p> <p>Background</p> <p>Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer (LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used serum marker in breast cancer.</p> <p>Methods</p> <p>We retrospectively investigated the role of CA 15-3 in conjunction with other clinico-pathological variables as a predictor of response and time to disease recurrence following treatment in LABC. Pre and post primary chemotherapy serum concentrations of CA 15-3 together with other variables were reviewed and related to four outcomes following primary chemotherapy (clinical response, pathological response, time to recurrence and time to progression). Persistently elevated CA 15-3 after PC was considered as consecutively high levels above the cut off point during and after PC.</p> <p>Results</p> <p>73 patients were included in this study. Patients received PC (AC or AC-T regimen) for locally advanced breast cancer. 54 patients underwent surgery. The median follow up was 790 days. Patients with high concentrations of CA 15-3 before PC treatment had a poor clinical (<it>p </it>= 0.013) and pathological (<it>p </it>= 0.044) response. Together with Her-2/neu expression (<it>p </it>= 0.009) and tumour lympho-vascular space invasion (LVI) (<it>p </it>= 0.001), a persistently elevated CA 15-3 post PC (<it>p </it>= 0.007) was an independent predictive factor of recurrence following treatment in LABC.</p> <p>Conclusion</p> <p>Elevated CA 15-3 level is predictive of a poor response to chemotherapy. In addition, persistently elevated CA 15-3 levels post chemotherapy in conjunction with lympho-vascular invasion and HER2 status predict a reduced disease free survival following treatment in locally advanced breast cancer.</p>http://www.biomedcentral.com/1471-2407/6/220 |
| spellingShingle | McDermott Enda W Myers Eddie Kelly Gabrielle Al-azawi Dhafir Hill Arnold DK Duffy Michael J Higgins Niall O CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer BMC Cancer |
| title | CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer |
| title_full | CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer |
| title_fullStr | CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer |
| title_full_unstemmed | CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer |
| title_short | CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer |
| title_sort | ca 15 3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer |
| url | http://www.biomedcentral.com/1471-2407/6/220 |
| work_keys_str_mv | AT mcdermottendaw ca153ispredictiveofresponseanddiseaserecurrencefollowingtreatmentinlocallyadvancedbreastcancer AT myerseddie ca153ispredictiveofresponseanddiseaserecurrencefollowingtreatmentinlocallyadvancedbreastcancer AT kellygabrielle ca153ispredictiveofresponseanddiseaserecurrencefollowingtreatmentinlocallyadvancedbreastcancer AT alazawidhafir ca153ispredictiveofresponseanddiseaserecurrencefollowingtreatmentinlocallyadvancedbreastcancer AT hillarnolddk ca153ispredictiveofresponseanddiseaserecurrencefollowingtreatmentinlocallyadvancedbreastcancer AT duffymichaelj ca153ispredictiveofresponseanddiseaserecurrencefollowingtreatmentinlocallyadvancedbreastcancer AT higginsniallo ca153ispredictiveofresponseanddiseaserecurrencefollowingtreatmentinlocallyadvancedbreastcancer |